ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.
Open access · bronzeAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 95 citations in OpenAlex.
- A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.Blood advances · 2022Trial
- Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.Blood advances · 2022Trial
- Immune Checkpoint Blockade in Hematological Malignancies: Current Status and Future Directions.Cancers · 2026Review
- Review
- A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.Annals of hematology · 2025Article
- The Emerging Role of CD8Cancers · 2025Review
- Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches.Clinical hematology international · 2025Review
- BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML.Science translational medicine · 2024Article
- PD-1H/VISTA mediates immune evasion in acute myeloid leukemia.The Journal of clinical investigation · 2024Article
- Inflammation as a driver of hematological malignancies.Frontiers in oncology · 2024Review
- The immunobiology of myelodysplastic neoplasms: a mini-review.Frontiers in immunology · 2024Review
- A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.Annals of hematology · 2024Article
- Immune checkpoint blockade in hematological malignancies: current state and future potential.Frontiers in oncology · 2024Review
- Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.Leukemia research · 2023Review
- Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress.Cancers · 2023Review
- An Overview of Targeted Therapies in Acute Myeloid Leukemia.HemaSphere · 2023Review
- Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.Signal transduction and targeted therapy · 2023Review
- High Co-Expression ofJournal of oncology · 2023Article
- Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.The Journal of clinical investigation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 1 country.
Amer M Zeidan *Section of Hematology, Department of Medicine, and the Smilow Cancer Center at Yale University, New Haven, Connecticut.
Hanna A Knaus *Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Tara M RobinsonSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Andrea M H TowlertonClinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington.
Edus H WarrenClinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington.
Joshua F ZeidnerLineberger Comprehensive Cancer Center at University of North Carolina, Raleigh, North Carolina.
Amanda L BlackfordSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Amy S DuffieldSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
David RizzieriDuke Cancer Institute, Durham, North Carolina.
Mark G FrattiniColumbia University Medical Center, New York, New York.ORCID 0000-0003-4924-8990
Yair M LevyTexas Oncology at Baylor University Medical Center, Dallas, Texas.
Mark A SchroederSiteman Cancer Center at Washington University, St. Louis, Missouri.
Anna FergusonSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Katherine E SheldonSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Amy E DeZernSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Ivana GojoSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
Steven D GoreSection of Hematology, Department of Medicine, and the Smilow Cancer Center at Yale University, New Haven, Connecticut.
Howard StreicherCancer Therapy Evaluation Program, NIH, Bethesda, Maryland.
Leo LuznikSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
B Douglas SmithSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. bdsmith@jhmi.edu.
Sidney Kimmel Comprehensive Cancer Center · USFred Hutch Cancer Center · USSmilow Cancer Hospital · USBaylor University Medical Center · USClinical Research Institute · USColumbia University Irving Medical Center · USJewish Hospital · USNorth Carolina State University · USTracer Technologies (United States) · US
Funding
ViKTriY-PC Consortium Phase II SupplementUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · 2014 to 2026
$22.2MThe Johns Hopkins Translational Science Team for the ET-CTNUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci · 2014 to 2026
$21.9MDuke-UNC-Wash U Partnership for Early Phase Clinical Trials in CancerUM1CA186704 · NCI · DUKE UNIVERSITY · PI ABBRUZZESE, JAMES L., DEES, ELIZABETH CLAIRE · 2014 to 2019
$6.8MWisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI JABBOUR, SALMA, LIU, GLENN · 2014 to 2019
$4.1MNCTN Lead Academic Participating Sites ApplicationU10CA180838 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAREY, LISA A · 2014 to 2018
$2.8MNCI NIH HHS U10 CA180838NCI NIH HHS UM1 CA186689NCI NIH HHS UM1 CA186691NCI NIH HHS UM1 CA186704NCI NIH HHS UM1 CA186716
Abstract
PubMed holds no abstract for this paper.
Indexed as
Administration, IntravenousAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCTLA-4 AntigenDNA MethylationDose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsFemaleHumansIpilimumabMaleMiddle AgedMyelodysplastic SyndromesT-LymphocytesTreatment OutcomeCTLA-4 AntigenIpilimumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.